Andexanet alfa: trials just leave us with more questions
Andexanet Alfa in Acute Intracranial Hemorrhage in Patients Receiving an Oral Factor Xa Inhibitor (ANNEXA-I), the first ever randomized controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomized patients with intracranial hemorrhage to and...
Saved in:
| Main Author: | Richard J. Buka |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Research and Practice in Thrombosis and Haemostasis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2475037924003236 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world andexanet alfa utilization and the association between delay in administration due to hospital transfer and all-cause inpatient mortality
by: Huiqiao Fan, et al.
Published: (2025-01-01) -
Definition of factor Xa inhibitor–related, life‐threatening gastrointestinal bleeding and guidance on when to use reversal therapy: A Delphi panel
by: Gregory J. Fermann, et al.
Published: (2023-10-01) -
Management of factor Xa inhibitor–related traumatic non‐intracranial bleeding events with andexanet alfa or four‐factor prothrombin complex concentrate in a US multicenter observational study
by: Paul P. Dobesh, et al.
Published: (2024-12-01) -
POSSIBILITIES OF INHIBITING ANTICOAGULANT ACTIVITIES THAT INHIBIT XA-FACTOR
by: A. D. Erlich
Published: (2019-06-01) -
Anticoagulant effects of edoxaban in cancer and noncancer patients with venous thromboembolism
by: Masashi Yoshida, et al.
Published: (2025-04-01)